Back to top

The current mutation

ID: V3509
DNA: 21224A>G
Protein: K7075R
Position: 21488








COV2Var annotation categories







Summary information of mutation (21224A>G)

Basic Information about Mutation.

  Gene Information   Gene ID   GU280_gp01_pp1ab
  Gene Name   ORF1ab_pp1ab
  Gene Type   protein_coding
  Genome position   21488
  Reference genome   GenBank ID: NC_045512.2
  Mutation type   missense_variant
  DNA Level   DNA Mutation: 21224A>G
  Ref Seq: A
  Mut Seq: G
  Protein Level   Protein 1-letter Mutation: K7075R
  Protein 3-letter Mutation: Lys7075Arg

Overview of the genomic positions of Mutation.
Note: The annotated 12 genes were retrieved from GeneBank (Accession: NC_045512.2). "MP" represents genomic position of mutation.





Analyzing the distribution of mutation (21224A>G) across geographic regions, temporal trends, and lineages

The count of genome sequences harboring this mutation and its distribution across global regions offer insights into regional variations.
Note: The distribution of mutation across 218 geographical regions. Color representation of genome sequence counts. The data is obtained from GISAID's metadata, specifically capturing the regional distribution of genomic sequences.



The dynamic count of genome sequences containing this mutation over time.
Note: Clicking the "Count" or "Cumulative Count" button toggles the view. Count represents the number of genome sequences per month. Cumulative count represents the accumulated total count up to the respective month. The data is obtained from GISAID's metadata, specifically capturing the collection date of genomic sequences.



For every time point represented in the graph above, identifying the top 3 lineages with the highest count of genome sequences carrying this mutation aids in pinpointing noteworthy lineages for further analysis.
Note: Users can filter the lineages by entering a "Year-Month" term in the search box. For example, entering 2020-01 will display lineages that appeared in January 2020. The data is obtained from GISAID's metadata, specifically capturing the collection date of genomic sequences.

Collection date Lineage Total lineage monthly counts Lineage-specific monthly counts Lineage-specific monthly frequency
2020-10 B.1.1.312 2 2 1.00e+0
2020-11 B.1.466.1 4 3 7.50e-1
2020-11 B.1.258 4 1 2.50e-1
2020-12 B.1.466.1 6 3 5.00e-1
2020-12 B.1.1.362 6 2 3.33e-1
2020-12 B.1.258 6 1 1.67e-1
2020-07 B.1 1 1 1.00e+0
2020-08 B.1.1.317 1 1 1.00e+0
2021-01 B.1.1.7 4 1 2.50e-1
2021-01 B.1.36 4 1 2.50e-1
2021-01 B.1.466.1 4 1 2.50e-1
2021-10 AY.121 2 1 5.00e-1
2021-10 AY.4 2 1 5.00e-1
2021-11 AY.103 4 1 2.50e-1
2021-11 AY.120 4 1 2.50e-1
2021-11 AY.43 4 1 2.50e-1
2021-12 AY.43 3 1 3.33e-1
2021-12 AY.46 3 1 3.33e-1
2021-12 BA.1.1 3 1 3.33e-1
2021-02 B.1.616 20 6 3.00e-1
2021-02 B.1.177.60 20 5 2.50e-1
2021-02 B.1.1.7 20 3 1.50e-1
2021-03 B.1.616 43 22 5.12e-1
2021-03 B.1.1.7 43 17 3.95e-1
2021-03 B.1.1.420 43 2 4.65e-2
2021-04 B.1.1.7 27 18 6.67e-1
2021-04 B.1.616 27 8 2.96e-1
2021-04 B.1.311 27 1 3.70e-2
2021-05 B.1.1.7 27 21 7.78e-1
2021-05 B.1.351 27 4 1.48e-1
2021-05 P.1 27 1 3.70e-2
2021-06 B.1.1.7 5 3 6.00e-1
2021-06 P.1 5 2 4.00e-1
2021-07 AY.43 3 2 6.67e-1
2021-07 AY.5 3 1 3.33e-1
2021-08 AY.42 17 6 3.53e-1
2021-08 AY.4 17 4 2.35e-1
2021-08 AY.43 17 2 1.18e-1
2021-09 C.37 15 9 6.00e-1
2021-09 AY.4 15 3 2.00e-1
2021-09 AY.103 15 1 6.67e-2
2022-01 BA.2 23 12 5.22e-1
2022-01 AY.43 23 3 1.30e-1
2022-01 BA.1.1 23 3 1.30e-1
2022-10 BA.5.2.27 3 1 3.33e-1
2022-10 BA.5.2.6 3 1 3.33e-1
2022-10 BF.10 3 1 3.33e-1
2022-11 BF.5 9 2 2.22e-1
2022-11 BQ.1 9 2 2.22e-1
2022-11 BA.5.1.23 9 1 1.11e-1
2022-12 BA.5.1.26 11 5 4.55e-1
2022-12 BA.1.1 11 1 9.09e-2
2022-12 BA.5 11 1 9.09e-2
2022-02 BA.2 58 50 8.62e-1
2022-02 BA.1.1 58 3 5.17e-2
2022-02 BA.1.1.1 58 3 5.17e-2
2022-03 BA.2 92 84 9.13e-1
2022-03 BA.1.1.1 92 3 3.26e-2
2022-03 BA.2.10 92 1 1.09e-2
2022-04 BA.2 42 38 9.05e-1
2022-04 BA.2.37 42 2 4.76e-2
2022-04 BA.1.1.2 42 1 2.38e-2
2022-05 BA.2 33 18 5.45e-1
2022-05 BA.2.56 33 11 3.33e-1
2022-05 BA.2.12 33 1 3.03e-2
2022-06 BA.2 28 14 5.00e-1
2022-06 BA.2.56 28 10 3.57e-1
2022-06 BA.2.3 28 1 3.57e-2
2022-07 BA.2.56 7 2 2.86e-1
2022-07 BE.1.1 7 2 2.86e-1
2022-07 BA.5.2.3 7 1 1.43e-1
2022-08 BF.7 9 4 4.44e-1
2022-08 BA.2 9 1 1.11e-1
2022-08 BA.5.1.22 9 1 1.11e-1
2022-09 BA.5.5 5 2 4.00e-1
2022-09 BA.5.1.12 5 1 2.00e-1
2022-09 BE.1 5 1 2.00e-1
2023-01 BA.5.1.26 17 3 1.76e-1
2023-01 BQ.1.3 17 2 1.18e-1
2023-01 XBB.1.5 17 2 1.18e-1
2023-02 XBB.1.9.1 9 6 6.67e-1
2023-02 BQ.1.1 9 2 2.22e-1
2023-02 BA.5.1.26 9 1 1.11e-1

The count of genome sequences and the frequency of this mutation in each lineage.
Note: Displaying mutation frequencies (>0.01) among 2,735 lineages. Mutation Count represents the count of sequences carrying this mutation. Users can filter the lineages by entering a search term in the search box. For example, entering "A.1" will display A.1 lineages. The data is obtained from GISAID's metadata, specifically capturing the lineage of genomic sequences. Mutation count: Count of sequences carrying this mutation.

Mutation ID Lineage Mutation frequency Mutation count Earliest lineage emergence Latest lineage emergence
V3509 B.1.466.1 5.07e-2 7 2020-6-9 2021-4-3
V3509 B.1.616 1.00e+0 37 2021-1-29 2021-4-23
V3509 BA.5.1.26 1.29e-2 10 2022-6-8 2023-2-16
V3509 CM.8 1.06e-2 2 2022-9-6 2023-2-5






Examining mutation (21224A>G) found in abundant sequences of non-human animal hosts

Exploring mutation presence across 35 non-human animal hosts for cross-species transmission.
Note: We retained the mutation that appear in at least three non-human animal hosts' sequences. The data is obtained from GISAID's metadata, specifically capturing the host of genomic sequences.

Animal host Lineage Source region Collection date Accession ID




Association between mutation (21224A>G) and patients of different ages, genders, and statuses

Note: The logistic regression model was employed to examine changes in patient data before and after the mutation. The logistic regression model was conducted using the glm function in R. The data is obtained from GISAID's metadata, specifically capturing the patient status, gender, and age of genomic sequences.

Analyzing the association between mutation and patient status.
Note: we categorized the data into different patient statuses (ambulatory, deceased, homebound, hospitalized, mild, and recovered) based on GISAID classifications. In the analysis exploring the association between mutation and patient status, the model included mutation, patient status, patient age, gender, sequence region of origin, and sequence collection time point. In the 'increase' direction of the mutation, it means that when this mutation occurs, it increases the corresponding effect proportion. In the 'decrease' direction of the mutation, it means that when this mutation occurs, it decreases the corresponding effect proportion. A p-value lower than 0.001 signifies a notable differentiation between the population with and without the mutation.

Attribute Effect Estimate SE Z-value P-value Direction
Patient status Ambulatory 8.42e-15 2.61e+5 3.23e-20 1.00e+0 Increase
Deceased -1.40e+1 2.71e+3 -5.16e-3 9.96e-1 Decrease
Homebound -1.97e+1 1.71e+4 -1.16e-3 9.99e-1 Decrease
Hospitalized -1.59e+1 1.88e+4 -8.43e-4 9.99e-1 Decrease
Mild 8.42e-15 2.61e+5 3.23e-20 1.00e+0 Increase
Recovered 1.78e+1 7.60e+3 2.34e-3 9.98e-1 Increase

Analyzing the association between mutation and patient status.
Note: we categorized the data into different patient age (0-17, 18-39, 40-64, 65-84, and 85+). In the analysis exploring the association between mutation and patient age, the model included mutation, patient age, gender, sequence region of origin, and sequence collection time point. In the 'increase' direction of the mutation, it means that when this mutation occurs, it increases the corresponding effect proportion. In the 'decrease' direction of the mutation, it means that when this mutation occurs, it decreases the corresponding effect proportion. A p-value lower than 0.001 signifies a notable differentiation between the population with and without the mutation.

Attribute Effect Estimate SE Z-value P-value Direction
Patient age, years 0-17 -1.57e+1 1.04e+3 -1.50e-2 9.88e-1 Decrease
18-39 -2.06e+0 5.67e-1 -3.63e+0 2.82e-4 Decrease
40-64 -6.79e-1 4.27e-1 -1.59e+0 1.12e-1 Decrease
65-84 2.02e+0 4.71e-1 4.30e+0 1.73e-5 Increase
>=85 2.13e+0 5.69e-1 3.75e+0 1.78e-4 Increase

Analyzing the association between mutation and patient status.
Note: we categorized the data into different patient gender (male and female). In the analysis exploring the association between mutation and patient gender, the model included mutation, patient gender, patient age, sequence region of origin, and sequence collection time point. In the 'increase' direction of the mutation, it means that when this mutation occurs, it increases the corresponding effect proportion. In the 'decrease' direction of the mutation, it means that when this mutation occurs, it decreases the corresponding effect proportion. A p-value lower than 0.001 signifies a notable differentiation between the population with and without the mutation.

Attribute Effect Estimate SE Z-value P-value Direction
Patient gender Male 1.00e-1 3.88e-1 2.59e-1 7.96e-1 Increase





Investigating natural selection at mutation (21224A>G) site for genetic adaptation and diversity

Note: Investigating the occurrence of positive selection or negative selection at this mutation site reveals implications for genetic adaptation and diversity.

The MEME method within the HyPhy software was employed to analyze positive selection. MEME: episodic selection.
Note: List of sites found to be under episodic selection by MEME (p < 0.05). "Protein Start" corresponds to the protein's starting genomic position. "Protein End" corresponds to the protein's ending genomic position. The term 'site' represents a selection site within the protein.

Protein name Protein start Protein end Protein length Site P-value Lineage Method

The FEL method within the HyPhy software was employed to analyze both positive and negative selection. FEL: pervasive selection on samll datasets.
Note: List of sites found to be under pervasive selection by FEL (p < 0.05). A beta value greater than alpha signifies positive selection, while a beta value smaller than alpha signifies negative selection. "Protein Start" corresponds to the protein's starting genomic position. "Protein End" corresponds to the protein's ending genomic position. The term 'site' represents a selection site within the protein.

Protein name Protein start Protein end Protein length Site Alpha Beta P-value Lineage Method
methyltransferase 20659 21552 298 277 46.39 0.00 4.00e-2 BA.5.2.24 FEL
methyltransferase 20659 21552 298 277 37.37 0.00 4.00e-2 AY.88 FEL
methyltransferase 20659 21552 298 277 9.05 0.71 4.00e-2 BA.5.2.6 FEL
methyltransferase 20659 21552 298 277 7.81 0.00 1.00e-2 AY.100 FEL
methyltransferase 20659 21552 298 277 52.23 0.00 5.00e-2 CA.1 FEL

The FUBAR method within the HyPhy software was employed to analyze both positive and negative selection. FUBAR: pervasive selection on large datasets.
Note: List of sites found to be under pervasive selection by FUBAR (prob > 0.95). A prob[alpha < beta] value exceeding 0.95 indicates positive selection, while a prob[alpha > beta] value exceeding 0.95 indicates negative selection. "Protein Start" corresponds to the protein's starting genomic position. "Protein End" corresponds to the protein's ending genomic position. The term 'site' represents a selection site within the protein.

Protein name Protein start Protein end Protein length Site Prob[alpha>beta] Prob[alpha<beta] Lineage Method
methyltransferase 20659 21552 298 277 9.80e-1 2.00e-2 AY.100 FUBAR




Alterations in protein physicochemical properties induced by mutation (21224A>G)

Understanding the alterations in protein physicochemical properties can reveal the evolutionary processes and adaptive changes of viruses
Note: ProtParam software was used for the analysis of physicochemical properties. Significant change threshold: A change exceeding 10% compared to the reference is considered a significant change. "GRAVY" is an abbreviation for "grand average of hydropathicity".

Group Protein name Molecular weight Theoretical PI Extinction coefficients Aliphatic index GRAVY
Mutation ORF1ab_pp1ab 794085.81 6.32 928150 86.87 -0.07
Reference ORF1ab_pp1ab 794057.79 6.32 928150 86.87 -0.07




Alterations in protein stability induced by mutation (21224A>G)

The impact of mutations on protein stability directly or indirectly affects the biological characteristics, adaptability, and transmission capacity of the virus
Note: iMutant 2.0 was utilized to analyze the effects of mutations on protein stability. pH 7 and a temperature of 25°C are employed to replicate the in vitro environment. pH 7.4 and a temperature of 37°C are utilized to simulate the in vivo environment.

Mutation Protein name Mutation type Position ΔDDG Stability pH Temperature Condition
K7075R ORF1ab_pp1ab Point 7075 -0.38 Decrease 7 25 Environment
K7075R ORF1ab_pp1ab Point 7075 -0.34 Decrease 7.4 37 Internal




Impact on protein function induced by mutation (21224A>G)

The impact of mutations on protein function
Note: The MutPred2 software was used to predict the pathogenicity of a mutation and gives the molecular mechanism of pathogenicity. A score above 0.5 indicates an increased likelihood of pathogenicity. "Pr" is the abbreviation for "proportion. P" is the abbreviation for "p-value.

Mutation Protein name Mutation type Score Molecular mechanisms
K7075R ORF1ab_pp1ab Point 0.097 Gain of Helix (Pr = 0.27 | P = 0.06)
Altered MoRF (Pr = 0.27 | P = 0.05)
Altered PPI_residue (Pr = 0.25 | P = 0.08)
Altered DNA_binding (Pr = 0.22 | P = 0.01)




Exploring mutation (21224A>G) distribution within intrinsically disordered protein regions

Intrinsically Disordered Proteins (IDPs) which refers to protein regions that have no unique 3D structure. In viral proteins, mutations in the disordered regions s are critical for immune evasion and antibody escape, suggesting potential additional implications for vaccines and monoclonal therapeutic strategies.
Note: The iupred3 software was utilized for analyzing IDPs. A score greater than 0.5 is considered indicative of an IDP. In the plot, "POS" represents the position of the mutation.





Alterations in enzyme cleavage sites induced by mutation (21224A>G)

Exploring the impact of mutations on the cleavage sites of 28 enzymes.
Note: The PeptideCutter software was used for detecting enzymes cleavage sites. The increased enzymes cleavage sites refer to the cleavage sites in the mutated protein that are added compared to the reference protein. Conversely, the decreased enzymes cleavage sites indicate the cleavage sites in the mutated protein that are reduced compared to the reference protein.

Mutation Protein name Genome position Enzyme name Increased cleavage sites Decreased cleavage sites
K7075R ORF1ab_pp1ab 21488 Arg-C proteinase LLSRGRLIIR (pos: 7075)
 NA
K7075R ORF1ab_pp1ab 21488 Clostripain (Clostridiopeptidase B) LLSRGRLIIR (pos: 7075)
 NA
K7075R ORF1ab_pp1ab 21488 LysC NA
 LLSKGRLIIR (pos: 7075)
K7075R ORF1ab_pp1ab 21488 LysN NA
 SLLSKGRLII (pos: 7074)




Impact of spike protein mutation (21224A>G) on antigenicity and immunogenicity

Investigating the impact of mutations on antigenicity and immunogenicity carries important implications for vaccine design and our understanding of immune responses.
Note: An absolute change greater than 0.0102 (three times the median across sites) in antigenicity score is considered significant. An absolute changegreater than 0.2754 (three times the median across sites) in immunogenicity score is considered significant. The VaxiJen tool was utilized for antigenicity analysis. The IEDB tool was used for immunogenicity analysis. Antigens with a prediction score of more than 0.4 for this tool are considered candidate antigens. MHC I immunogenicity score >0, indicating a higher probability to stimulate an immune response.

Group Protein name Protein region Antigenicity score Immunogenicity score




Impact of mutation (21224A>G) on viral transmissibility by the affinity between RBD and ACE2 receptor

Unraveling the impact of mutations on the interaction between the receptor binding domain (RBD) and ACE2 receptor using deep mutational scanning (DMS) experimental data to gain insights into their effects on viral transmissibility.
Note: The ΔBinding affinity represents the disparity between the binding affinity of a mutation and the reference binding affinity. A positive Δbinding affinity value (Δlog10(KD,app) > 0) signifies an increased affinity between RBD and ACE2 receptor due to the mutation. Conversely, a negative value (Δlog10(KD,app) < 0) indicates a reduced affinity between RBD and ACE2 receptor caused by the mutation. A p-value smaller than 0.05 indicates significance. "Ave mut bind" represents the average binding affinity of this mutation. "Ave ref bind" refers to the average binding affinity at a site without any mutation (reference binding affinity).

;
Mutation Protein name Protein region Mutation Position Ave mut bind Ave ref bind ΔBinding affinity P-value Image


The interface between the receptor binding domain (RBD) and ACE2 receptor is depicted in the crystal structure 6JM0.
Note: The structure 6M0J encompasses the RBD range of 333 to 526. The binding sites (403-406, 408, 417, 439, 445-447, 449, 453, 455-456, 473-478, 484-498, and 500-506) on the RBD that interface with ACE2 are indicated in magenta. The binding sites on the RBD that have been identified through the interface footprints experiment. The ACE2 binding sites within the interface are shown in cyan, representing residues within 5Å proximity to the RBD binding sites. The mutation within the RBD range of 333 to 526 is depicted in red.

        Show as:

        Show interface residues:





Impact of mutation (21224A>G) on immune escape by the affinity between RBD and antibody/serum

By utilizing experimental data from deep mutational scanning (DMS), we can uncover how mutations affect the interaction between the receptor binding domain (RBD) and antibodies/serum. This approach provides valuable insights into strategies for evading the host immune response.
Note: We considered a mutation to mediate strong escape if the escape score exceeded 0.1 (10% of the maximum score of 1). A total of 1,504 antibodies/serum data were collected for this analysis. "Condition name" refers to the name of the antibodies/serum. "Mut escape score" represents the escape score of the mutation in that specific condition. "Avg mut escape score" indicates the average escape score of the mutation site in that condition, considering the occurrence of this mutation and other mutations. Class 1 antibodies bind to an epitope only in the RBD “up” conformation, and are the most abundant. Class 2 antibodies bind to the RBD both in “up” and “down” conformations. Class 3 and class 4 antibodies both bind outside the ACE2 binding site. Class 3 antibodies bind the RBD in both the open and closed conformation, while class 4 antibodies bind only in the open conformation.

Mutation Condition name Condition type Condition subtype Condition year Mut escape score Avg mut escape score




Investigating the co-mutation patterns of mutation (21224A>G) across 2,735 viral lineages

Investigating the co-mutation patterns of SARS-CoV-2 across 2,735 viral lineages to unravel the cooperative effects of different mutations. In biological research, correlation analysis of mutation sites helps us understand whether there is a close relationship or interaction between certain mutations.
Note: The Spearman correlation coefficient is used to calculate the correlation between two mutations within each Pango lineage. Holm–Bonferroni method was used for multiple test adjustment. We retained mutation pairs with correlation values greater than 0.6 or less than -0.6 and Holm–Bonferroni corrected p-values less than 0.05.

Associated mutation ID DNA mutation Mutation type Protein name Protein mutation correlation coefficient Lineage
V8870 1887T>C synonymous_variant S L629L 8.94e-1 BF.7
V7207 10074T>C synonymous_variant ORF1ab_pp1a N3358N 7.07e-1 AY.120
V3620 335C>T missense_variant S S112L 1.00e+0 AY.43.3
V7153 9684A>G synonymous_variant ORF1ab_pp1a E3228E 1.00e+0 AY.43.3
V9226 627A>G synonymous_variant ORF3a S209S 1.00e+0 AY.43.3
V7445 11976C>T synonymous_variant ORF1ab_pp1a D3992D 7.07e-1 AY.46
V2689 15143C>T missense_variant ORF1ab_pp1ab A5048V 1.00e+0 AY.61
V3500 21176C>T missense_variant ORF1ab_pp1ab S7059F 7.07e-1 B.1.1.317
V4281 3754T>C missense_variant S S1252P 1.00e+0 B.1.1.317
V1456 6178G>T missense_variant ORF1ab_pp1a D2060Y 7.07e-1 B.1.1.420
V2766 15943G>T missense_variant ORF1ab_pp1ab A5315S 7.07e-1 B.1.1.420
V3332 20030A>G missense_variant ORF1ab_pp1ab Y6677C 7.07e-1 B.1.1.420
V451 1204C>T missense_variant ORF1ab_pp1a R402C 6.32e-1 B.1.177.60
V3399 20419G>T missense_variant ORF1ab_pp1ab V6807F 6.32e-1 B.1.258
V4072 2338G>C missense_variant S E780Q 6.32e-1 B.1.258
V4058 2203T>G missense_variant S S735A 7.74e-1 B.1.36
V4114 2611G>T missense_variant S A871S 7.07e-1 B.1.36
V468 1285G>A missense_variant ORF1ab_pp1a A429T 7.07e-1 B.1.36
V4753 224G>T missense_variant M W75L 6.54e-1 B.1.36
V5656 1250C>T missense_variant N T417I 6.67e-1 B.1.36
V5695 29C>T missense_variant ORF10 P10L 6.67e-1 B.1.36
V950 3221C>T missense_variant ORF1ab_pp1a A1074V 7.74e-1 B.1.36
V4387 145G>A missense_variant ORF3a G49S 7.07e-1 BA.2.12
V2337 12248C>T missense_variant ORF1ab_pp1a T4083M 7.07e-1 BA.2.24
V3015 17899A>G missense_variant ORF1ab_pp1ab I5967V -7.07e-1 BA.2.24
V1812 8395C>T missense_variant ORF1ab_pp1a H2799Y 8.66e-1 BA.2.56
V5020 40_41delTT frameshift_variant ORF7b L14fs 8.26e-1 BA.2.56
V6882 7593C>T synonymous_variant ORF1ab_pp1a N2531N 8.18e-1 BA.2.56
V7711 14098C>T synonymous_variant ORF1ab_pp1ab L4700L 9.40e-1 BA.2.56
V2410 12794C>T missense_variant ORF1ab_pp1a T4265I 7.07e-1 BA.5.1.12
V1965 9583A>G missense_variant ORF1ab_pp1a S3195G 1.00e+0 BA.5.1.24
V3869 1331A>C missense_variant S K444T 1.00e+0 BA.5.1.24
V5630 1154G>A missense_variant N R385K 7.07e-1 BA.5.1.24
V9562 24T>C synonymous_variant N N8N 1.00e+0 BA.5.1.24
V5415 518C>T missense_variant N A173V 6.30e-1 BA.5.1.26
V7019 8652C>T synonymous_variant ORF1ab_pp1a F2884F 9.53e-1 BA.5.1.26
V7401 11691C>T synonymous_variant ORF1ab_pp1a D3897D 8.93e-1 BA.5.1.26
V851 2873A>G missense_variant ORF1ab_pp1a K958R 9.12e-1 BA.5.1.26
V950 3221C>T missense_variant ORF1ab_pp1a A1074V 6.30e-1 BA.5.1.26
V1703 7750G>A missense_variant ORF1ab_pp1a A2584T 1.00e+0 BA.5.2.27
V4281 3754T>C missense_variant S S1252P 1.00e+0 BA.5.2.27
V9398 21T>C synonymous_variant ORF6 F7F 1.00e+0 BA.5.2.27
V1136 4145C>T missense_variant ORF1ab_pp1a A1382V 7.07e-1 BF.7.6
V131 85C>T missense_variant ORF1ab_pp1a R29C 7.07e-1 BF.7.6
V1486 6267G>T missense_variant ORF1ab_pp1a E2089D 1.00e+0 BN.1.3
V5373 361C>A missense_variant N L121I 1.00e+0 BN.1.5
V8075 16878T>C synonymous_variant ORF1ab_pp1ab A5626A 1.00e+0 BN.1.5
V2117 10829C>T missense_variant ORF1ab_pp1a A3610V 1.00e+0 BN.3.1
V6411 3927T>C synonymous_variant ORF1ab_pp1a T1309T 1.00e+0 BN.3.1
V8628 66T>C synonymous_variant S T22T 7.07e-1 BQ.1.1.13
V2594 14143C>T missense_variant ORF1ab_pp1ab P4715S 7.07e-1 BQ.1.1.18
V7498 12489C>T synonymous_variant ORF1ab_pp1a C4163C 1.00e+0 BQ.1.28
V90 -38C>T upstream_gene_variant ORF1ab_pp1a None 1.00e+0 BQ.1.28
V2791 16210A>G missense_variant ORF1ab_pp1ab S5404G 7.07e-1 BQ.1.3
V1658 7447C>T missense_variant ORF1ab_pp1a P2483S 7.35e-1 C.37
V2126 10859C>T missense_variant ORF1ab_pp1a A3620V 6.21e-1 C.37
V3894 1424C>T missense_variant S A475V 8.58e-1 C.37
V3909 1450G>A missense_variant S E484K 7.25e-1 C.37
V3928 1502A>C missense_variant S N501T 6.45e-1 C.37
V6639 5628C>T synonymous_variant ORF1ab_pp1a T1876T 6.70e-1 C.37
V6829 7128G>A synonymous_variant ORF1ab_pp1a P2376P 6.52e-1 C.37
V9256 807G>T synonymous_variant ORF3a T269T 7.89e-1 C.37
V5752 *4342T>C downstream_gene_variant S None 6.11e-1 XBB.1.9.1
V9512 54A>G synonymous_variant ORF8 Q18Q 9.43e-1 XBB.1.9.1
V66 -63C>T upstream_gene_variant ORF1ab_pp1a None 7.06e-1 B.1.1.312
V7168 9765C>T synonymous_variant ORF1ab_pp1a T3255T 7.06e-1 B.1.1.362
V9099 3577T>C synonymous_variant S L1193L 1.00e+0 B.1.1.362
V6894 7716A>G synonymous_variant ORF1ab_pp1a L2572L 1.00e+0 B.1.466.1
V864 2912C>T missense_variant ORF1ab_pp1a P971L 1.00e+0 B.1.466.1
V1989 9851C>T missense_variant ORF1ab_pp1a T3284I 7.05e-1 CM.8
V4953 248C>T missense_variant ORF7a S83L 7.05e-1 CM.8
V9178 234C>T synonymous_variant ORF3a H78H 7.05e-1 CM.8





Manual curation of mutation (21224A>G)-related literature from PubMed

The pubmed.mineR and pubmed-mapper were utilized for extracting literature from PubMed, followed by manual filtering.
Note: PubMed: (COVID-19 [Title/Abstract] OR SARS-COV-2 [Title/Abstract]) AND (DNA mutation [Title/Abstract] OR Protein mutation-1 letter [Title/Abstract] OR Protein mutation-3 letter [Title/Abstract]).

DNA level Protein level Paper title Journal name Publication year Pubmed ID